Rubric Capital Management LP Has $16.98 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Rubric Capital Management LP lifted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report) by 54.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,024,500 shares of the company’s stock after purchasing an additional 1,423,121 shares during the quarter. Rubric Capital Management LP owned 1.31% of Amneal Pharmaceuticals worth $16,983,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aigen Investment Management LP bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth $118,000. Assenagon Asset Management S.A. raised its holdings in shares of Amneal Pharmaceuticals by 122.4% during the third quarter. Assenagon Asset Management S.A. now owns 515,233 shares of the company’s stock worth $2,174,000 after acquiring an additional 283,524 shares during the period. Tejara Capital Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth $408,000. EAM Investors LLC acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth $972,000. Finally, WINTON GROUP Ltd raised its holdings in shares of Amneal Pharmaceuticals by 172.3% during the third quarter. WINTON GROUP Ltd now owns 51,922 shares of the company’s stock worth $219,000 after acquiring an additional 32,854 shares during the period. 31.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on AMRX shares. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, January 29th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. Finally, Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $5.40.

Get Our Latest Research Report on AMRX

Amneal Pharmaceuticals Stock Performance

Shares of AMRX traded down $0.19 during midday trading on Wednesday, reaching $5.52. The stock had a trading volume of 1,800,741 shares, compared to its average volume of 1,330,745. The firm has a 50 day simple moving average of $5.66 and a 200-day simple moving average of $4.71. Amneal Pharmaceuticals, Inc. has a one year low of $1.24 and a one year high of $6.30. The firm has a market cap of $1.69 billion, a PE ratio of 92.00 and a beta of 1.34. The company has a current ratio of 1.91, a quick ratio of 1.16 and a debt-to-equity ratio of 16.75.

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

See Also

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.